Compare HCWB & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | ISPC |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.7M |
| IPO Year | 2021 | 2021 |
| Metric | HCWB | ISPC |
|---|---|---|
| Price | $1.61 | $0.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 141.6K | ★ 446.6K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $422,026.00 | ★ $3,352,744.00 |
| Revenue This Year | $178.64 | $35.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.84 | $0.39 |
| 52 Week High | $41.20 | $4.66 |
| Indicator | HCWB | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 28.88 | 38.28 |
| Support Level | $1.89 | $0.39 |
| Resistance Level | $2.15 | $0.53 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 2.94 | 25.03 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.